Immunosuppression for management of Crohn's disease

Affiliations

¹ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK. Electronic address: compare-team@ebmdatalab.net.
² Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.

Comment

Ioan Milosevic et al. Lancet. 2016.

. 2016 Feb 20;387(10020):747.

doi: 10.1016/S0140-6736(16)00326-3. Epub 2016 Feb 18.

¹ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK. Electronic address: compare-team@ebmdatalab.net.
² Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.

No abstract available

Comment in

Immunosuppression for management of Crohn's disease - Author's reply.
Khanna R; REACT investigators. Khanna R, et al. Lancet. 2016 Feb 20;387(10020):748. doi: 10.1016/S0140-6736(16)00011-8. Epub 2016 Feb 18. Lancet. 2016. PMID: 26906663 No abstract available.

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.
Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG; REACT Study Investigators. Khanna R, et al. Lancet. 2015 Nov 7;386(10006):1825-34. doi: 10.1016/S0140-6736(15)00068-9. Epub 2015 Sep 3. Lancet. 2015. PMID: 26342731 Clinical Trial.